Secondary measles vaccine failures identified by measurement of IgG avidity: High occurrence among teenagers vaccinated at a young age

Epidemiology and Infection

Volumn 124, Issue 2, 2000, Pages 263-271

  Paunio, M ^a   Hedman, K ^d   Davidkin, I ^b   Valle, M ^b   Heinonen, O P ^d   Leinikki, P ^b   Salmi, A ^d   Peltola, H ^c  

^a Sosiaali ja terveysministerio   (Finland)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; MEASLES VACCINE;

ANTIBODY DETECTION; ARTICLE; CHILD; DISEASE SEVERITY; HIGH RISK POPULATION; HUMAN; IMMUNITY; INFANT; MAJOR CLINICAL STUDY; MEASLES; MEASLES VIRUS; PUBLIC HEALTH; SEROCONVERSION;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGE FACTORS; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; CHILD; CHILD, PRESCHOOL; DISEASE OUTBREAKS; FEMALE; FINLAND; HUMANS; IMMUNOGLOBULIN G; MALE; MEASLES; MEASLES VACCINE; TIME FACTORS; TREATMENT FAILURE; VACCINATION;

EID: 0034048271     PISSN: 09502688     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0950268899003222     Document Type: Article

References (41)

1. de Quadros CA, Olive JM, Hersh BS, et al. Measles elimination in the Americas. JAMA 1996; 275: 224-9.
2. Rosenthal SR, Clements CJ. Two-dose measles vaccination schedules. Bull WHO 1993; 71: 421-8.
3. Markowitz LE, Preblud SR, Fine PEM, Orenstein WA. Duration of live measles vaccine-induced immunity. Pediatr Infect Dis J 1990; 9: 101-10.
4. US Preventive Services Task Force. Immunizations and chemoprophylaxis. Childhood immunizations. In: DiGuiseppi C, Atkins D. Woolf SH, eds. Guide to clinical preventive services, 2nd edn. Baltimore: Williams & Wilkins, 1996: 767-90.
5. Aaby P, Bukh J, Leerhoy J, Lisse IM, Mordhorst CH, Pedersen R. Vaccinated children get milder measles infection: a community study from Guinea-Bissau. J Infect Dis 1986; 154: 858-63.
6. Chen RT, Markowitz LE, Albrecht P, et al. Measles antibody: reevaluation of protective titers. J Infect Dis 1990; 162: 1036-42.
7. Ammari LK, Bell LM, Hodinka RL. Secondary measles vaccine failure in healthcare workers exposed to infected patients. Infect Control Hosp Epidemiol 1993; 14: 81-6.
8. Mathias RG, Meekison WG, Arcand TA, Schehter MT. The role of secondary vaccine failure in measles outbreaks. Am J Public Health 1989; 79: 475-8.
9. Söderlund M, Brown C, Cohen B, Hedman K. Accurate serodiagnosis of B19 parvovirus infections by measurement of IgG avidity. J Infect Dis 1995; 171: 710-3.
10. Binley MB, Arshad H, Fouts TR, Moore JP. An investigation of the high-avidity antibody response to glycoprotein 120 of human immunodeficiency virus type 1. AIDS Res Human Retrovir 1997; 13: 1007-15.
11. Hedman K. Seppälä I. Recent rubella virus infection indicated by a low avidity of specific IgG. J Clin Immunol 1988; 8: 214-21.
12. Tuokko H. Detection of acute measles infections by indirect and u-capture enzyme immunoassays for immunoglobulin M antibodies and measles immunoglobulin G antibody avidity enzyme immunoassay. J Med Virol 1995; 45: 306-11.
13. de Souza VAUF, Pannuti CS, Sumita LM, de Andrade HF. Enzyme-linked immunosorbent assay-IgG antibody avidity test for single sample serologic evaluation of measles vaccines. J Med Virol 1997; 52: 275-9.
14. Matsuzono Y, Narita M, Satake A, et al. Measles encephalomyelitis in a patient with a history of vaccination. Acta Paediatr JPN 1995; 37: 374-6.
15. Narita M, Yamada S, Matsuzono Y, Itakura O, Togashi T, Kikuta H. Immunoglobulin G avidity testing in serum and cerebrospinal fluid for analysis of measles virus infection. Clin Diagn Lab Immunol 1996; 3: 211-5.
16. Peltola H, Karanko V, Kurki T, et al. Rapid effect of endemic measles, mumps, and rubella of nationwide vaccination programme in Finland. Lancet 1986; i: 137-9.
17. Paunio M, Virtanen M, Peltola H, et al. Increase of vaccination coverage by mass media and individual approach: intensified measles, mumps, and rubella prevention program in Finland. Am J Epidemiol 1991; 133: 1152-60.
18. Peltola H, Heinonen OP, Valle M, et al. The elimination of indigenous measles, mumps, and rubella by a 12-year, two-dose vaccination program. N Engl J Med 1994; 331: 1397-402.
19. Paunio M, Peltola H, Valle M, Davidkin I, Virtanen M. Heinonen OP. Twice vaccinated are better protected against measles in epidemic conditions compared to single dose recipients of measles containing vaccine. J Epidemiol Comm Health 1999; 53: 173-81.
20. Paunio M, Peltola H, Valle M, Davidkin I, Virtanen M, Heinonen OP. Explosive school based outbreak -intense exposure may have resulted in high measles risk even among the re-vaccinees. Am J Epidemiol 1998; 148: 1103-10.
21. Gershon AA, Krugman S. Measles virus. In: Lennette EH, Schmidt NJ, eds. Diagnostic procedures for viral, rickettsial and chlamydial infections. 5th ed. Washington, D. C.: American Public Health Association, 1979: 685-6.
22. Hedman K, Lappalainen M, Seppälä I, Mäkelä O. Recent primary toxoplasma infection indicated by a low avidity of specific IgG. J Infect Dis 1989; 159: 736-40.
23. Hedman K, Lappalainen M, Söderlund M, Hedman L. Avidity of IgG in serodiagnosis of infectious diseases. Rev Med Microbiol 1993; 4: 123-9.
24. Erdman DD, Heath JL, Watson JC, Markowitz LE, Bellini WJ. Immunoglobulin M antibody response to measles virus following primary and secondary vaccination and natural virus infection. J Med Virol 1993; 41: 44-8.
25. Davidkin I, Valle M. Vaccine-induced measles antibodies after two doses of combined measles, mumps and rubella vaccine: a 12-year follow-up in two cohorts. Vaccine 1998; 16: 2052-7.
26. Edmonson MB, Addiss DG, McPherson T, Berg JL, Circo SR, Davis JP. Mild measles and secondary vaccine failure during a sustained outbreak in a highly vaccinated population. JAMA 1990; 263: 2467-71.
27. Welliver RC, Cherry JD, Holtzman AE. Typical, modified and atypical measles. Arch Intern Med 1977; 137: 39-41.
28. Cherry JD, Feigin RD, Shackelford PG, Hinthorn DR, Schmidt RR. A clinical and serological study of 103 children with measles vaccine failure. Pediatrics 1973; 82: 802-8.
29. Reyes MA, de Borrero MF, Roa J, Bergonzoli G, Saraviak NG. Measles vaccine failure after documented seroconversion. Pediatr Infect Dis J 1987; 6: 848-51.
30. Armitage P, Berry G. Comparison of several groups. In: Statistical methods in medical research, 2nd edn. Oxford: Blackwell Scientific Publications, 1987: 200-5.
31. Armitage P, Berry G. Distribution free methods. In: Statistical methods in medical research, 2nd edn, Oxford: Blackwell Scientific Publications, 1987: 411-2.
32. Greenland S, Robins JM. Estimation of a common parameter from sparse follow-up data. Biometrics 1985; 41: 55-68.
33. Siegel S, Castellan (Jr) NJ. Two independent samples. In: Nonparametric statistics for the behavioral sciences. 2nd edn. Singapore: McGraw-Hill international editions, statistics series, 1989: 103-11.
34. Ozanne G, D'Halewyn M-A. Secondary immune response in a vaccinated population during a large measles epidemic. J Clin Microbiol 1992; 30: 1778-82.
35. Anders JF, Jacobson RM, Poland GA, Jacobsen SJ, Wollan PC. Secondary failure rates of measles vaccines: a meta-analysis of published studies. Pediatr Infect Dis J 1996; 15: 62-6.
36. Whittle HC, Aaby P, Samb B, Jensen H, Bennett J, Simondon F. Effect of subclinical infection on maintaining immunity against measles in vaccinated children in West Africa. Lancet 1999; 353: 98-102.
37. Pedersen IR, Mordhorst CH, Glikmann G, von Magnus H. Subclinical measles infection in vaccinated seropositive individuals in arctic Greenland. Vaccine 1989; 7: 345-8.
38. Ward BJ, Boulianne SR, Guiot MC, Couillard M, De Serres G. Cellular immunity in measles vaccine failure: demonstration of measles antigen-specific lympho-proliferative responses despite limited serum antibody production after re-vaccination. J Infect Dis 1995; 172: 1591-5.
39. Poland GA, Jacobsen RM, Thampy AM, et al. Measles reimmunization in children seronegative after initial immunization. JAMA 1997; 277: 1156-8.
40. Matter L, Kogelschatz K, Germann D. Serum levels of rubella virus antibodies indicating immunity: response to vaccination of subjects with low or undetectable antibody concentrations. J Infect Dis 1997; 175: 749-55.
41. Goldblatt D, Pinto Vaz ARJP, Miller E. Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization. J Infect Dis 1998; 177: 1112-5.